As blockbuster drugs go off patent, the pharmaceutical industry is scrambling for fresh revenue sources. Follow-on versions of biologics, or “biosimilars,” are being pitched as BigPharma’s saving grace. One question remains unaddressed in the discussion: is anyone actually planning on selling biosimilars in the United States? What are biosimilars? Biosimilars are a new class of [...]
The views expressed are those of the author(s) and are not necessarily those of Scientific American.